Penumbra, Inc. (PEN)
| Market Cap | 5.44B |
| Revenue (ttm) | 782.28M |
| Net Income (ttm) | -6.47M |
| Shares Out | 37.68M |
| EPS (ttm) | 0.14 |
| PE Ratio | 1,032.21 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 397,154 |
| Open | 147.92 |
| Previous Close | 150.82 |
| Day's Range | 143.27 - 150.00 |
| 52-Week Range | 130.96 - 293.20 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 263.67 (+82.5%) |
| Earnings Date | May 3, 2022 |
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is 263.67, which is an increase of 82.46% from the latest price.
News
Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why
Penumbra Inc (NYSE: PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance. Wells Fargo lowered the price target to $265 from 321, whi...
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra, Inc. Reports First Quarter 2022 Financial Results
ALAMEDA, Calif. , May 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March ...
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra, Inc. to Present at the Bank of America Securities 2022 Healthcare Conference
ALAMEDA, Calif. , April 26, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference ...
Penumbra Announces the European Launch of the Indigo® System With Lightning™ 7 and Lightning 12 Intelligent Aspiration
ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc.'s Indigo Aspiration System with Lightning 7 and Lightning 12 have secured CE Mark and are now commercially available in Europe.
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have a history of creating shareholder value -- and still have plenty of room for growth.
Penumbra, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 3, 2022
ALAMEDA, Calif. , April 5, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market close ...
Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform
ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. introduces the REAL® Immersive System y-Series™ with significantly more activities and experiences.
Penumbra, Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
ALAMEDA, Calif. , March 28, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on M...
These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
Looking for small healthcare companies with huge revenue opportunities? Try these.
Down 16% In A Month, Will Penumbra Stock Rebound?
The stock price of Penumbra, a medical devices company focused on interventional therapies, has seen a 16% fall in a month, while it was down 10% last week. The company reported mixed Q4 results last mo...
Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%
Penumbra Inc (NYSE: PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4% (3...
Wall Street Analysts Believe Penumbra (PEN) Could Rally 40%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positive...
Penumbra (PEN) Q4 Earnings Lag Estimates
Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full y...
Earnings Preview: Penumbra (PEN) Q4 Earnings Expected to Decline
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra, Inc. to Present at Citi's 2022 Virtual Healthcare Conference
ALAMEDA, Calif., Feb. 10, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2022 Virtual Healthcare Conference on Thursday, Febru...
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 22, 2022
ALAMEDA, Calif., Feb. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2021 after ...
Penumbra Weighing Combination With Shockwave Medical: Bloomberg
Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV), Bloomberg reported citing people with knowledge of the matter. According to the people, Penumbra has hel...
Penumbra, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
ALAMEDA, Calif., Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40th Annual J.P.
Penumbra's Thrombectomy System Shows Safety, Clinical Benefit
Penumbra Inc (NYSE: PEN) announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter met the primary endpoint. As part of the Indigo Aspiration System, the Indigo CAT RX Aspiration Ca...
New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with Penumbra's Indigo® System CAT...
ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #mechanicalthrombectomy--CHEETAH study demonstrates safety and performance of continuous aspiration thrombectomy for coronary blood clots with Penumbra's Indigo...
Penumbra (PEN) Lags Q3 Earnings Estimates
Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Penumbra, Inc. Reports Third Quarter 2021 Financial Results
ALAMEDA, Calif., Nov. 3, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended Septem...